Travere Therapeutics Inc Ordinary Shares TVTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TVTX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $9.77
- Day Range
- $9.69–10.12
- 52-Week Range
- $5.12–17.57
- Bid/Ask
- $9.87 / $12.00
- Market Cap
- $752.92 Mil
- Volume/Avg
- 672,629 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.13
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- < 0.01%
Company Profile
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 380
- Website
- https://www.travere.com
Comparables
Valuation
|
Metric
|
TVTX
|
MORF
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 10.16 | 4.58 | 1.84 |
Price/Sales | 4.13 | — | 3,220.91 |
Price/Cash Flow | — | — | — |
Price/Earnings
TVTX
MORF
PLRX
Financial Strength
|
Metric
|
TVTX
|
MORF
|
PLRX
|
|---|---|---|---|
Quick Ratio | 2.68 | 23.71 | 15.95 |
Current Ratio | 2.78 | 24.13 | 16.12 |
Interest Coverage | −36.28 | — | −138.69 |
Quick Ratio
TVTX
MORF
PLRX
Profitability
|
Metric
|
TVTX
|
MORF
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −9.49% | −20.07% | −23.39% |
Return on Equity (Normalized) | −42.23% | −20.72% | −25.61% |
Return on Invested Capital (Normalized) | −14.33% | −24.50% | −29.08% |
Return on Assets
TVTX
MORF
PLRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Vgmqmyrgw | Vpnq | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wpjkbmyy | Zzdmwl | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Sgrdxxv | Knvxj | $118.7 Bil | |||
| Moderna Inc
MRNA
| Cspcrxql | Jdttr | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vxxjlzlwn | Vxrwc | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Kvvfhhljq | Gwx | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Qdbrytjp | Wzr | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Yptwntw | Htbgjrd | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Ydxrtpct | Msk | $15.0 Bil | |||
| Incyte Corp
INCY
| Tfryvrxq | Srnbn | $13.5 Bil |